About the Continued Evaluation of MK-1084 for NSCLC and More

Commentary
Video

Carlos Rojas, MD, discusses the next steps for evaluating MK-1084 in a phase 1 trial for the first-line treatment of metastatic non-small cell lung cancer and advanced solid tumors.

Carlos Rojas, MD, medical oncology, Centro de Investigacion Clinica, Bradford Hill, discusses the next steps for evaluating MK-1084 in a phase 1 trial (NCT05067283) for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) and advanced solid tumors.

MK-1084 is a selective KRAS G12C inhibitor. In the open-label, global, dose-escalation, phase 1 study, investigators are assessing the agent alone in patients with advanced solid tumors, as well as in combination with pembrolizumab (Keytruda) for the first-line treatment of metastatic NSCLC.

Transcription:

0:09 | We will open new arms for colorectal and for non-small cell lung cancer in [the] frontline in both, and in colorectal cancer, also in later lines in combination with cetuximab. And also, we will try another formulation of the drug looking for a best response in patients with any tumor that harbored this mutation.

0:38 | Another thing that is important, because 1 of the questions is well, we had sotorasib and adagrasib, [but] there will be another pharma developing drugs for this target. But I think that it is important to have more competition and more drugs. At least in countries like mine, I am not from a highly developed country, and when [we] have more options, the access to the drugs will be easier. So that is also an important thing because when [we] have a high number of drugs for the same target, and all the drugs are good drugs, I think that will [make it] easier for countries like mine to have access to these new treatments.

REFERENCE:
Rojas C. Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC. Presented at: ESMO 2023; September 29 - October 3, 2023; Madrid, Spain. Abstract 663P.

Recent Videos
1 KOL is featured in this series.
Presented by the Onc Brothers
Presented by the Onc Brothers
Presented by the Onc Brothers
Presented by the Onc Brothers
The Oncology Brothers with Joshua K. Sabari, MD, presenting slides
Related Content